Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography.

A high-performance liquid chromatographic (HPLC) method is described for the simultaneous determination of a fluoroquinolone, pefloxacin, and its main active metabolite norfloxacin (N-desmethyl metabolite) in serum. Sample preparation involves protein precipitation with acetonitrile. The drugs and the internal standard (acebutolol) were eluted from a 4-microns Novapak C-18 cartridge at ambient temperature with an isocratic mobile phase consisting of 14% acetonitrile in buffer solution, at a flow rate of 2.5 ml/min. The effluent was monitored on a fluorescence detector using excitation and emission wave-lengths of 330 and 440 nm, respectively. Each analysis required no longer than 8 min. Quantification was achieved by measurement of the peak-area ratio of the drugs to the internal standard, and the limit of quantification for both pefloxacin and norfloxacin in serum was 50 ng/ml. The intraday coefficient of variation (CV) ranged from 1.3 to 4.4% and from 2.2 to 7.5% for pefloxacin and norfloxacin, respectively, at the concentration ranges evaluated. The interday CV ranged from 1.1 to 5.9% and from 2.3 to 5.6% for pefloxacin and norfloxacin, respectively, at three concentrations. Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively. Stability tests show that pefloxacin and norfloxacin are stable in serum for at least 3 weeks when stored at -20 degrees C. This method has been used successfully in pharmacokinetic studies in humans.

[Determination of elimination of pefloxacin and of its derivatives in continuous hemodiafiltration]. / Détermination de l'élimination de la péfloxacine et de ses dérivés en hémodiafiltration continue.

Continuous venovenous hemofiltration with dialysis (CVVHD) is being increasingly used to treat acute renal failure. However, because of the-lack of data on the clearance of therapeutic agents during this treatment, there is a risk of using inappropriate dosages. This in vitro study was undertaken to determine the clearance of pefloxacin (P) and its two main metabolites (active N-desmethyl P and inactive N-oxide P) during CVVHD. Acitrate-dextrose (ACD) anticoagulated fresh human blood containing P and its two metabolites in the usual therapeutic levels was circulated at a rate of 100 ml min.-1 through a closed-circuit continuous venovenous hemofiltration with dialysis unit (BSM 22-Hospal hemofilter). Temperature and ionic composition of the blood were controlled. Dialysate (L2D, Hospal) was circulated on the other side of the continuous venovenous hemofiltration with dialysis membrane at three different flow rates (Qdi) (0, 500 and 1,000 ml.h-1. The dialysate/ultrafiltrate outflow was adjusted using a withdrawal pump to obtain nul ultrafiltration. Arterial blood, venous blood and ultrafiltrate were sampled simultaneously at different time points for High Performance Liquid Chromatography (HPLC) assays and determination of the clearances (Cl) and sieving coefficients (s) of each compound. Pefloxacin had a sieving coefficient of 0.42 and a clearance of 6.8 ml min-1 when Qdi was nul. With the blood flow used, clearances were found to be correlated with the dialysate flow rate; when this rate was 500 ml h-1, a pefloxacin clearance similar to that seen in healthy subjects was obtained (15.2 ml min-1). The two bacteriologically active forms of the drug (pefloxacin and N-desmethyl P) had similar elimination parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Antimicrobial activity and interaction of pefloxacin and its principal metabolites. Collaborative Antimicrobial Susceptibility Testing Group.

The in vitro antimicrobial activity of pefloxacin and its major metabolites was determined and the interaction of pefloxacin and N-demethyl pefloxacin (norfloxacin) assessed at the ratio naturally occurring in urine (1:2). Pefloxacin and N-demethyl pefloxacin had approximately the same spectrum but were markedly more active than N-oxide pefloxacin (MIC90s greater than or equal to 64 micrograms/ml) against 867 stock strains. When combined with N-demethyl pefloxacin, pefloxacin had greater potency and a broader spectrum in tests against 5869 fresh clinical organisms. For approximately 10% more strains pefloxacin MICs were less than or equal to 2 micrograms/ml when pefloxacin was combined with 2 parts (4 micrograms/ml) of N-demethyl pefloxacin. The most significant extension of the pefloxacin spectrum was to include non-enteric gram-negative bacilli (inhibition of 67% versus 88%) and enterococci-streptococci (inhibition of 33% versus 86%). These results are similar to those previously noted for enoxacin plus 3-oxo-enoxacin, and potentially achievable with other newer fluoro-quinolones undergoing significant metabolism.

Studies on prodrugs. 7. Synthesis and antimicrobial activity of 3-formylquinolone derivatives.

Several 3-formylquinolone derivatives (8a-c) were synthesized to assay the antibacterial activity both in vitro and in vivo. In vitro, all of the compounds 8a-c showed lower activity than that of the corresponding 3-carboxyl compounds 1a-c, and in vivo, they showed higher activity than that of compounds 1a-c. After oral administration of 3-formyl compounds 8a-c to mice, the compounds were rapidly metabolized into 3-carboxyl compounds 1a-c. In particular, the 3-formyl derivative (8a) of norfloxacin (NFLX, 1a) gave a 2-fold higher serum level than that of NFLX and functioned as a prodrug of NFLX.